Non-Invasive Measures of Distal Lung Disease in Asthmatics

This study has been completed.
Information provided by:
Teva Branded Pharmaceutical Products, R&D Inc. Identifier:
First received: November 4, 2005
Last updated: March 31, 2008
Last verified: March 2008

This is a Phase 4, single center study conducted in mild-to moderate asthmatics.

Condition Intervention Phase
Drug: QVAR
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Teva Branded Pharmaceutical Products, R&D Inc.:

Primary Outcome Measures:
  • High resolution Cat Scans

Estimated Enrollment: 34
Study Start Date: September 2005
Study Completion Date: September 2007
Detailed Description:

The study consists of 3 phases. There are 7 study visits.


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18-65 years old
  • Currently using SABA prn or a low-to-moderate persistent asthma

Exclusion Criteria:

  • Tobacco use within 1 year or >= 5 pack years
  Contacts and Locations
Please refer to this study by its identifier: NCT00250341

United States, California
Los Angeles, California, United States, 90095
Sponsors and Collaborators
Teva Branded Pharmaceutical Products, R&D Inc.
Principal Investigator: Michelle Zeidler, MD University of California, Los Angeles
  More Information

No publications provided Identifier: NCT00250341     History of Changes
Other Study ID Numbers: IXR-403-4-196
Study First Received: November 4, 2005
Last Updated: March 31, 2008
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on April 16, 2014